



FINANCIAL RESULTS

Fiscal Year Ending March 2026

JEOL Ltd.
May 15, 2026

Summary of FY2025 Financial Results

FY2025 Results

- Operating profit increased by ¥2.0 billion from the previously announced forecast of ¥24.0 billion to ¥26.0 billion, while net profit reached a record high and ROE was 15.7%.
【Net sales】 ¥179.4 billion (YoY -8.8%)
【Operating profit】 ¥26.0 billion (YoY -26.7%)
【Exchange rates】 ¥151/USD, ¥175/EUR
- **Scientific/Metrology Instruments** : Revenue and profit declined due mainly to a rebound decline following strong demand driven by supplementary budgets in China in the previous fiscal year, as well as the impact of reductions in science and technology-related budgets in the United States.
- **Industrial Equipment** : Unit sales of Multi-Beam Mask Writers and Single-Beam Mask Writers declined year on year. Meanwhile, demand for spot-beam electron beam lithography systems expanded for use in production applications, including the ramp-up of DFB laser production for optical transceivers used in AI data centers.
- **Medical Equipment** : The business was transferred to Sysmex Corporation on April 1, 2026.

FY2026 Forecast

- Although uncertainty remains due to reductions in science and technology-related budgets in the United States, inquiries centered on electron microscopes are expected to remain firm.
- While signs of recovery are emerging in the market environment for Multi-Beam Mask Writers, demand recovery is still expected to take time, and performance is forecast to remain at approximately the same level as the previous fiscal year.
【Net sales】 ¥164.0 billion (reflecting the impact of the transfer of the Medical Equipment Business)
【Operating profit】 ¥26.5 billion
【Exchange rates】 ¥155/USD, ¥175/EUR

※ Details of the FY2026 business outlook and updates to the medium-term management plan will be explained at the financial results briefing scheduled for May 29.

FY2025 Results (P/L)

- Net sales were ¥179.4 billion (YoY -8.8%), and operating profit was ¥26.0 billion (YoY -26.7%).

Consolidated figures (P/L)

			(100 million JPY)
	FY24 Result	FY25 Result	YoY
1 Net sales	1,967	1,794	- 173
2 Sales cost	1,043	963	- 80
3 (Cost ratio)	53.0%	53.7%	0.7%
4 Gross profit	924	830	- 94
5 SGA	449	456	7
6 R&D cost	120	114	- 6
7 SGA total	569	570	1
8 Operating profit	355	260	- 95
9 Non-operating income	12	29	17
10 Non-operating expenses	23	3	- 20
11 Ordinary profit	344	286	- 58
12 Extraordinary income	29	11	- 18
13 Extraordinary loss	124	2	- 122
14 Net profit before taxes	250	295	45
15 Corporate taxes	63	74	11
16 Net profit	187	221	34
Exchange rate (1\$=)	¥152	¥151	
Exchange rate (1€=)	¥164	¥175	


Factors for fluctuating ordinary profit (YoY)

(100 million JPY)	
(A) Positive Factors	8
1.R&D cost decrease	6
2.FX impact (yen depreciation)	2
(B) Negative factors	-103
1.Sales volume decrease	-84
2.Higher cost of sales (including product mix changes, etc.)	-12
3.SGA increase	-7
(A)+(B)	-95

Factors of Increase/Decrease in Profit

Operating Profit Analysis

(100 million JPY)



Transition of Consolidated Sales & Operating Profit by Segment (Result)

(100 million JPY)

		FY24 Result①	FY25 Result②	YoY (②-①)	YoY %
Company Total	Net sales	1,967	1,794	-173	-8.8%
	Operating profit	355	260	-95	-26.7%
	OP margin	18.0%	14.5%	-3.5%	-
	Ordinary profit	344	286	-58	-16.9%
	Net profit	187	221	34	18.2%
Scientific/Metrology Instruments	Net sales	1,248	1,163	-85	-6.8%
	Operating profit	150	131	-19	-13.0%
	OP margin	12.0%	11.2%	-0.8%	-
Industrial Equipment	Net sales	565	481	-84	-14.8%
	Operating profit	263	194	-70	-26.4%
	OP margin	46.6%	40.2%	-6.4%	-
Medical Equipment	Net sales	154	149	-5	-3.2%
	Operating profit	7	1	-6	-90.3%
	OP margin	4.3%	0.4%	-3.9%	-
Company total	Expenses	65	65	0	-0.2%
	Exchange rate (1\$=)	¥152	¥151	¥-1	-0.7%
	Exchange rate (1€=)	¥164	¥175	¥11	6.7%

Change in Major Accounts

(100 million JPY)

(Consolidated)	FY24 Result	FY25 result
1 Inventory	770	755
2 Interest-bearing debt	76	252
3 Total assets	2,225	2,240
4 Net Assets (capital-to-asset)	1,367 (61.4%)	1,449 (59.9%)
5 Dividend(JPY)	106	132
6 Capital investment	70	202
7 Depreciation cost	49	54
8 Consolidated orders received	1,864	1,801
9 Consolidated order backlog	1,032	1,039
10 Overseas sales ratio	71.2%	67.2%


Investment efficiency index

1 ROE	14.3%	15.7%
2 ROIC*	18.1%	12.3%
3 PBR	1.7	1.9

* In accordance with our internal management standard

Transition of Consolidated Orders, Sales and Backlog

(100 million JPY)



Completion of Transfer of the Medical Equipment Business

- On April 1, 2026, the Company completed the transfer of its Medical Equipment Business to Sysmex Corporation, and the business commenced operations as “Sysmex BioMajesty Co., Ltd.”.

Company Profile

Company Name	Sysmex BioMajesty Co., Ltd.
Location	2-11-1 Inadaira, Musashimurayama-shi, Tokyo
Representative	Mineharu Takayama, Representative Director
Establishment Date	April 1, 2026
Capital	95 million yen
Business Description	Manufacturing, sales, research and development of medical equipment, as well as contract processing of related products and components, maintenance and services, and procurement and sales of peripheral equipment



Completion of Share Repurchase and Tender Offer for Own Shares


- The Company positions its capital policy—integrating the promotion of growth investments, the maintenance of financial soundness, and the enhancement of capital efficiency—as one of its key management priorities aimed at maximizing corporate value over the medium to long term. Taking into consideration the business environment and growth opportunities, the Company’s fundamental approach is to enhance per-share value on a sustainable basis by pursuing optimal capital structure and balance sheet management with a clear focus on capital costs.
- On February 2, 2026, the Company resolved to conduct a share repurchase and tender offer for its own shares, with a maximum total acquisition price of approximately 12.8 billion yen and a maximum acquisition of 2,500,100 shares.
- The tender offer commenced on February 3, 2026, and was completed on March 4, 2026.
- The Company will continue to steadily implement various management initiatives under its medium-term management plan to enhance capital efficiency and achieve sustainable growth in corporate value.

Results of Share Repurchase and Tender Offer for Own Shares

Total acquisition price	11,840,420,592 yen
Total number of shares acquired	2,300,004 shares, equivalent to 4.46% of total issued shares

Initiatives for stable and continuous return to shareholders

- Aim to realize stable and continuous shareholder returns based on a basic policy of a target dividend payout ratio of 30%.
- The Company will consider flexible share repurchases aimed at enhancing capital efficiency and achieving sustainable growth in corporate value.
(Repurchased 2.3 million shares for approximately 11.8 billion yen in FY2025)
- The Company's policy is to manage the cancellation of treasury shares while maintaining an appropriate level of treasury share holdings, with a view to maximizing corporate value.



Note on document handling

Information contained in this document is based on assumptions and beliefs derived from currently available data. Actual results may differ materially due to various known and unknown factors, including economic trends, semiconductor industry cycles, and changes in R&D spending.

© 2026 JEOL Ltd.